Commercial
Commercial, Wednesday 24 April 2024
Commercial
11:24Chair's Remarks
Afshan Hussain, Managing Director, Global Rare Disease Lead, Havas Life Rare
Commercial
11:25NIH as your technology development and commercialization partner
Michael Salgaller, Supervisor, Technology Analysis and Marketing Unit (TAMU), National Institute of Health (NIH)
Commercial
11:45Commercialization in rare disease
Lindy Forte, Senior Vice President, Market Access and Pricing, EVERSANA
Commercial
12:05Building commercial teams for a successful pre-launch
Moderator: Kevin Baruzzi, Partner, Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Wills Hughes-Wilson, Chief Patient Access & Commercial Planning, Mereo Biopharma
Ron Cooper, Former CEO, Albireo Pharma
Jason Tardio, Chief Operating Officer, Ovid Therapeutics
Commercial
12:45Patient engagement strategy earlier in commercial planning
Melissa Williams, Founder, Simply Patient
Commercial
13:05Meet the moment for advanced therapies: Past learnings, present state and collaborating for the future
Michael Lehmicke, Senior Vice President of Science and Industry Affairs, Alliance for Regenerative Medicine
Shaun Ellis, Vice President, Global Market Access Specialty Ophthalmology, Johnson & Johnson
Commercial
14:59Chair's Remarks
Afshan Hussain, Managing Director, Global Rare Disease Lead, Havas Life Rare
Commercial
15:00Use of machine learning to improve time to diagnosis of patients with probable MPS II: A case study
Pierantonio Russo, FCCP, FAAP, STS, Corporate Chief Medical Officer, EVERSANA
Ramaa Nathan, VP of Data Science and Real-World Evidence, EVERSANA
Commercial
15:20Commercializing in the ultra-orphan space: Unique challenges and opportunities
Moderator: Kristin Marvin-Keller, Managing Director, Havas Life Rare
Commercial
16:00What it takes to order that one test by physicians
Moderator: Christine Yu, Chief Executive Officer, P2P Syncro
Gay Grossman, Co-Founder and Patient Advocate, ADCY5.org
Pierantonio Russo, FCCP, FAAP, STS, Corporate Chief Medical Officer, EVERSANA
Erik Feingold, CEO & Co-Founder, FDNA, Inc
last published: 19/Apr/24 23:05
Commercial, Thursday 25 April 2024
Commercial
11:59Chair's Remarks
Inderpreet Kambo, Principal (Partner) - Information Management & Analytics, IQVIA
Commercial
12:00Preparing early for ex-US commercialisation – a patient access perspective
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Commercial
12:20AI, insights and technology transformations within rare diseases
Inderpreet Kambo, Principal (Partner) - Information Management & Analytics, IQVIA
Commercial
12:40Transformative launch strategies: Commercializing orphan products for success
Moderator: Simone Seiter, Senior Partner, Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Grant Castor, SVP Commercial Strategy & Operations, Sentynl Therapeutics
Tsveta Milanova, Chief Commercial Officer, Agios Pharmaceuticals
Neha Kumar, Global Commercial Strategy - Precision Medicine, Johnson & Johnson Innovative Medicine
Commercial
13:20Rescuing ‘orphaned’ drug programs & creating a viable commercial pathway for ultra-rare disease treatments
Craig Martin, President, Rithm Health; CEO, Orphan Therapeutics Accelerator
last published: 19/Apr/24 23:05
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events